Tyra Biosciences (NASDAQ:TYRA) Earns Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research note released on Friday,RTT News reports. The brokerage currently has a $30.00 price objective on the stock. Wedbush also issued estimates for Tyra Biosciences’ FY2029 earnings at ($0.91) EPS.

TYRA has been the topic of several other research reports. UBS Group started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $9.77 on Friday. The company has a market cap of $494.39 million, a price-to-earnings ratio of -6.07 and a beta of 1.09. The stock’s fifty day moving average price is $12.46 and its two-hundred day moving average price is $16.30. Tyra Biosciences has a 52-week low of $9.49 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. On average, equities analysts predict that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Activity

In related news, Director Nina S. Kjellson sold 3,993 shares of Tyra Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 21,998 shares of company stock valued at $344,818 in the last ninety days. 15.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds have recently bought and sold shares of TYRA. Janus Henderson Group PLC acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at $24,994,000. Rhumbline Advisers grew its stake in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after acquiring an additional 1,027 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Tyra Biosciences in the third quarter worth about $593,000. Barclays PLC raised its position in shares of Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock worth $884,000 after purchasing an additional 25,106 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.